Home › Trials › NCT06738771

Assessing treatments for difficult-to-treat Pseudomonas infections

Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study

Observational Centre Hospitalier Régional d'Orléans · NCT06738771

This study is testing different antibiotic treatments for tough Pseudomonas infections to see which ones work best for patients needing intravenous therapy.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorCentre Hospitalier Régional d'Orléans Academic / other
Locations48 sites (Amiens and 47 other locations)
Trial IDNCT06738771 on ClinicalTrials.gov

What this trial studies

The ADDICT study aims to evaluate the clinical efficacy of various antimicrobial therapies for infections caused by difficult-to-treat Pseudomonas aeruginosa. This prospective, multicenter cohort study will include patients requiring intravenous therapy for these infections, comparing newer beta-lactam/beta-lactamase inhibitor combinations and cefiderocol against older agents like aminoglycosides and colistin. The study will also investigate the emergence of drug resistance and the associated adverse events. By gathering multicenter data, the study seeks to provide insights into the real-life effectiveness of these treatment options.

Who should consider this trial

Good fit: Ideal candidates are patients aged 18 or older who require intravenous antimicrobial therapy for a difficult-to-treat Pseudomonas aeruginosa infection.

Not a fit: Patients with cystic fibrosis or those who do not require definitive intravenous antibiotic therapy for their Pseudomonas infection may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with difficult-to-treat Pseudomonas infections.

How similar studies have performed: While there is limited multicenter data on the real-life utilization of these treatment options, previous studies have shown promising results with similar approaches.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection

Exclusion Criteria:

* Cystic fibrosis
* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy
* Protected person (under guardianship or curatorship)
* Persons under court protection
* Persons deprived of liberty
* Opposition expressed for participation in the study

Where this trial is running

Amiens and 47 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Pseudomonas InfectionsPseudomonas AeruginosaPrognosisDrug Resistance, Multiple, BacterialAntibacterial AgentsBeta-lactam Antibiotics
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.